CTS (CTS) Margin Expansion Challenges Slowing Growth Concerns Ahead Of Q1 2026

CTS (CTS) opened Q1 2026 with Q4 2025 revenue of US$137.3 million and basic EPS of US$0.68, alongside trailing twelve month revenue of US$541.3 million and EPS of US$2.21 that reflect a 17.7% earnings increase over the past year. Over the last six reported quarters, revenue has moved from US$126.5 million in Q4 2024 to US$137.3 million in Q4 2025, while quarterly EPS has ranged between US$0.38 and US$0.68. This gives investors a clear view of how the top and bottom line have tracked into the current print. With trailing net margins at 12.1% versus 10.8% a year earlier, the latest results present a cleaner profitability profile and frame how investors might weigh the balance between earnings power and future growth.

See our full analysis for CTS.

With the numbers on the table, the next step is to see how this earnings profile lines up against the most common narratives around CTS, highlighting where the story is reinforced and where expectations might need adjusting.

See what the community is saying about CTS

Margins and EPS Outpace Revenue

• On a trailing basis, CTS earned US$65.3 million of net income on US$541.3 million of revenue, with EPS of US$2.21 and a 12.1% net margin compared with 10.8% a year earlier.
• Analysts' consensus view points to CTS moving up the value chain in areas like aerospace or defense and industrial automation, and the margin profile so far lines up with that idea, but investors still have to weigh that against weaker transportation and certain medical lines that are flagged as broad based challenges in the narrative.
  • Net margin at 12.1% gives some support to the idea that higher value offerings and operational efficiency are feeding through to profitability.
  • At the same time, the consensus narrative highlights soft transportation sales and uneven medical demand as ongoing pressure points that could limit how far margins can stretch if those end markets remain mixed.

Earnings Growth Slows From 27.4% Pace

• Five year trailing earnings growth averaged 27.4% per year, while the most recent one year growth was 17.7% and forecasts sit around 9.8% per year, which is slower than both the earlier trend and the cited US market forecast of 16.2% per year.
• For a bullish angle that leans on diversification into higher growth medical and industrial markets, these growth rates give a mixed scoreboard, because the business is still growing earnings but at a more measured pace than the longer term average and below broader market expectations.
  • Consensus narrative points to demand for sensors and connectivity in automation and electrification as long term drivers, yet the moderation from 27.4% to 17.7% and then to a roughly 9.8% forecast growth rate suggests that momentum is less aggressive than the headline story might imply.
  • Analysts also expect margins to rise from 12.1% to 14.0% over three years, so part of the bullish case rests on further margin lift rather than a sharp acceleration in top line growth.

On this set of numbers, bulls are essentially betting that margin expansion and higher value products can keep earnings growing even as growth rates cool versus the last five years, and that is where the long form bullish narrative can help you stress test those assumptions against specific end markets and products 🐂 CTS Bull Case.

Valuation Sits Just Below DCF Fair Value

• CTS currently trades at US$54.43 per share, a slight discount to the DCF fair value estimate of about US$55.94 and close to the analyst price target of US$54.00, with a P/E of 23.9x versus a peer average of 80.8x and industry average of 26.9x.
• Skeptical investors who worry that slower forecast growth and weaker transportation demand could cap the upside may see this near alignment between price, DCF fair value and the analyst target as a sign that much of the current story is already reflected in the market.
  • The roughly 2.7% gap between the share price and DCF fair value and the small difference between the share price and the US$54.00 analyst target leave limited implied upside based purely on those reference points.
  • With revenue expected to grow about 4.6% per year, below the cited 11.1% US market rate, critics highlight that CTS may need continued margin gains and disciplined capital allocation to justify meaningfully higher multiples from here.

For anyone weighing that cautious angle, it is worth reading through the full bear case to see how concerns around transportation exposure, competition and revenue pacing stack up against the current valuation markers 🐻 CTS Bear Case.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for CTS on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If this article left you with mixed feelings about CTS, consider turning that into an edge by reviewing the positives for yourself and weighing them against the risks in your portfolio, starting with the 3 key rewards.

See What Else Is Out There

CTS shows moderating earnings growth, softer revenue pacing than the broader US market and mixed transportation and medical demand that could limit further margin expansion.

If you are concerned that this slower growth and uneven demand might cap your upside, it is worth comparing these results with 52 high quality undervalued stocks that may offer a stronger balance between price and earnings potential.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com